Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)
ESMO Gastrointest. Oncol.
2026
11
The Role of Alcohol in Pancreatic Diseases: A Comprehensive Perspective.
Gastroenterology
2026
170
2
268-286
Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model.
Clin Gastroenterol Hepatol
2026
24
5
1321-1331
ACTN4 p.Ile150Met Causes FSGS With Validation in Primary Fibroblasts and Immortalized Podocytes.
Kidney Int Rep
2026
11
2
Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice.
Kidney Int
2026
109
1
211-216
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.
Am J Kidney Dis
2026
87
4
553-563.e1
Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care.
Ann Hepatol
2026
31
1
Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023.
Kidney Int
2026
109
1
57-63
Alport Syndrome is a Partial Tubulointerstitial Disease of the Kidney.
Kidney Int Rep
2026
11
2
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.
Am J Kidney Dis
2026
87
4
564-568